Key HighlightsThe US Supreme Court declined to hear Eli Lilly's challenge to the False Claims Act'sWhistleblowerprovisions, leaving in place a legal framework that allows private citizens to sue on behalf of the government for healthcareFraud.The ruling preserves the qui tam mechanism that has been …
Key HighlightsRegeneron Pharmaceuticals receivedWall Streetdowngrades after its immunotherapy combination therapy failed to demonstrate superiority to Merck's Keytruda in a head-to-head melanoma trial.The trial result is a significant setback for Regeneron's oncology pipeline, which had been expected to generate a meaningful new indication that would …
Key HighlightsGoldman Sachs set a new price target on Biogen, reflecting revised assumptions about the commercial trajectory of its Alzheimer's diseaseFranchisefollowing the latest clinical and market data.Biogen's Alzheimer's programme, centred on the amyloid-targeting antibody Leqembi developed with Eisai, represents one of the most commercially …
Key HighlightsNovo Nordisk's Wegovy pill is maintaining a strong lead over Eli Lilly's oral GLP-1 rival in prescriptionVolumemetrics, according to Citi analysts tracking weekly prescription data.The competitive dynamics in the oral obesity medication market are intensifying as both companies attempt to extend their injectable …
Key HighlightsWhirlpool's CEO issued a stark warning that current consumer spending patterns resemble those observed during the 2008 financial crisis, citing declining big-ticket applianceDemandand rising consumer stress indicators.The comparison to 2008 is significant because it implies that consumer weakness has moved beyond the energy-driven …
The sharpReversalin shares of TransMedics Group, Inc. (NASDAQ: TMDX) highlights a familiar dynamic unfolding across high-growth healthcare technology companies: investors remain willing to tolerate temporary earnings pressure when long-term structural growth remains intact.
Key Highlights
Key Highlights